aBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada;
bFaculty of Medicine, University of British Columbia, Vancouver, Canada;
cSimon Fraser University, Burnaby, British Columbia;
dNorthern Health Authority, Prince George, British Columbia;
eFraser Health Authority, Surrey, British Columbia; and
fInterior Health Authority, Kelowna, British Columbia.
Correspondence to: David M. Moore, MDCM, BC Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, BC V6T 1Y6, Canada (e-mail: [email protected]).
Some components of this study were presented at the 2020 Conference on Retroviruses and Opportunistic Infections; March 8–11, 2020; Boston, MA (Abstract # 1103).
Supported by the British Columbia Ministry of Health. The BC HIV Drug Treatment Program is funded by the BC Ministry of Health through the Pharmacare Program. J.S.G.M. has received institutional grants from Gilead Sciences, J&J, Merck, ViiV Healthcare. J.S.G.M. has also served as an advisor to the Government of Canada and the Government of British Columbia in the last year. D.M.M. is supported by a Scholar Award from the Michael Smith Foundation for Health Research. The remaining authors have no conflicts of interest to disclose.
